In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edison Pharmaceuticals Inc.

www.edisonpharma.com

Latest From Edison Pharmaceuticals Inc.

Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Research and Development Strategies Cancer

Rett Syndrome Drug Could Propel Newron To Next Level In 2018

Newron Pharmaceuticals will file its investigational drug sarizotan in 2018 for respiratory issues in patients with Rett syndrome, setting it up to be the first therapy specifically indicated for this rare genetic disease. CEO Stefan Weber spoke to Scrip about Newron's commercial strategy for sarizotan and broader prospects for the evolving drug developer.

Rare Diseases Business Strategies

Decibel Therapeutics: Protect. Repair. Restore.

Emerging Company Profile: Decibel Therapeutics, a Boston-based company focused on developing therapies for hearing loss, started adding its voice in an emerging development space in 2015, with the aim of becoming "the premier hearing therapies company." With ongoing research and preclinical candidates for hearing loss, Decibel is looking to secure a beneficial collaboration that will bump up its profile and give it the funding it needs to move forward.

StartUps and SMEs Research & Development

Stealth BioTherapeutics Looks Ahead To Phase III In Mitochondrial Disease

Stealth BioTherapeutics is planning Phase III trials on the back of positive Phase II data for its lead product elamipretide in the rare indication of mitochondrial dysfunction, a disease for which there no currently approved treatments.

Clinical Trials Therapy Areas
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Edison Pharmaceuticals Inc.
  • Senior Management
  • Guy Miller, MD, PhD, Chmn. & CEO
    Martin J Thoolen, PhD, Chief Drug Dev. Officer
    Keith Tsukimura, Sr. Dir. & Controller, Fin.
  • Contact Info
  • Edison Pharmaceuticals Inc.
    Phone: (650) 641-9200
    350 N. Bernardo Ave.
    Mountain View, CA 94043
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register